TARS

Business Context and Reporting Period

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, primarily in eye care. The company's sole approved product, XDEMVY (lotilaner ophthalmic solution) 0.25%, was FDA-approved in July 2023 for the treatment of Demodex blepharitis and commercially launched in August 2023. This filing covers the quarterly period ended June 30, 2024.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The filing does not provide explicit gross margin percentages, but Cost of Sales was $3.0 million for the quarter and $4.7 million for the six months.

Material Changes vs. Prior Period

• Revenue Growth: The company recognized $40.8 million in product sales for the quarter ended June 30, 2024, compared to zero in the prior year period. This represents a 65% increase in product sales from Q1 2024 to Q2 2024.
• Expense Increases: Selling, general, and administrative (SG&A) expenses increased significantly to $58.8 million for the quarter (from $20.3 million in Q2 2023) due to the expansion of the commercial sales force and marketing efforts for XDEMVY.
• Debt Restructuring: In April 2024, the company executed a new $75.0 million credit facility with Pharmakon Advisors, LP, using proceeds to repay its previous credit facility. This resulted in a $1.9 million loss on debt extinguishment recorded in the quarter.
• China Out-License Transition: The company transitioned its China out-license rights from LianBio to GrandPharma in March 2024, recognizing $2.9 million in license fees and collaboration revenue for the six-month period (including termination and warrant cancellation payments).

Guidance, Outlook, and Risks

• Commercial Outlook: Management expects to deploy approximately 50 additional sales force representatives by the end of Q3 2024. Gross-to-net discounts improved to 44% in Q2 2024 from 55% in Q1 2024, with a target steady-state gross-to-net discount in the low 40s for 2025.
• Pipeline Progress: The company announced positive topline results for TP-03 (MGD), TP-04 (Rosacea), and TP-05 (Lyme disease prophylaxis) and plans to discuss regulatory paths with the FDA by the end of 2024.
• Liquidity: Management estimates existing capital resources ($323.6 million in cash and investments) are sufficient to fund operations for at least the next 12 months. However, the company anticipates continued significant operating losses and may require additional capital to achieve long-term goals.
• Risks: Key risks include the company's limited operating history, heavy dependence on the commercial success of XDEMVY, reliance on third-party manufacturers, and the potential for unfavorable pricing or reimbursement policies. The company also faces risks related to the transition of its China partner and the need to maintain intellectual property rights licensed from Elanco.

Investor Verification Checklist

• Commercial Execution: Verify the rate of new payer coverage contracts and the actual gross-to-net discount trends in upcoming quarters to assess revenue sustainability.
• Cash Burn Rate: Monitor the monthly burn rate given the significant increase in SG&A expenses and the timeline for achieving profitability.
• Debt Covenants: Review the specific milestones required to access the additional tranches ($25M, $50M, $50M) under the new 2024 Credit Facility.
• China Partnership: Confirm the status of the Novation Agreement with GrandPharma and the likelihood of achieving future regulatory milestones in the China Territory.
• Regulatory Filings: Track the outcomes of the planned FDA discussions regarding the regulatory path for TP-03 (MGD), TP-04 (Rosacea), and TP-05 (Lyme disease) later in 2024.